271,720 Shares in Prothena Corporation plc $PRTA Acquired by Penbrook Management LLC

Penbrook Management LLC bought a new position in Prothena Corporation plc (NASDAQ:PRTA) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 271,720 shares of the biotechnology company’s stock, valued at approximately $2,641,000. Prothena makes up approximately 2.0% of Penbrook Management LLC’s investment portfolio, making the stock its 12th biggest holding.

A number of other hedge funds have also recently made changes to their positions in PRTA. Focused Wealth Management Inc increased its holdings in shares of Prothena by 93.0% in the first quarter. Focused Wealth Management Inc now owns 207,403 shares of the biotechnology company’s stock worth $2,016,000 after purchasing an additional 99,924 shares during the period. Seven Fleet Capital Management LP bought a new stake in Prothena during the fourth quarter valued at $414,000. XTX Topco Ltd grew its position in Prothena by 247.2% during the fourth quarter. XTX Topco Ltd now owns 54,881 shares of the biotechnology company’s stock worth $524,000 after buying an additional 39,073 shares in the last quarter. Virtus Investment Advisers LLC grew its position in Prothena by 14.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 25,679 shares of the biotechnology company’s stock worth $245,000 after buying an additional 3,236 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC increased its stake in Prothena by 103.1% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 58,853 shares of the biotechnology company’s stock worth $562,000 after acquiring an additional 29,878 shares during the last quarter. 97.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Prothena

In other news, major shareholder William P. Scully bought 20,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was acquired at an average price of $7.90 per share, with a total value of $158,000.00. Following the completion of the purchase, the insider directly owned 756,000 shares in the company, valued at $5,972,400. This represents a 2.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders purchased a total of 345,000 shares of company stock valued at $3,097,250 over the last ninety days. 10.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

PRTA has been the topic of several recent analyst reports. Stifel Nicolaus set a $19.00 price target on Prothena in a report on Friday, March 13th. Wall Street Zen upgraded shares of Prothena from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Citizens Jmp lifted their target price on shares of Prothena from $19.00 to $20.00 and gave the company a “market outperform” rating in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Prothena from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Finally, Citigroup reissued an “outperform” rating on shares of Prothena in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Prothena presently has a consensus rating of “Moderate Buy” and an average target price of $23.75.

Prothena Stock Down 1.4%

Shares of PRTA stock opened at $9.27 on Friday. The business has a 50-day moving average price of $9.74 and a two-hundred day moving average price of $9.52. Prothena Corporation plc has a 12-month low of $5.83 and a 12-month high of $11.80. The firm has a market cap of $485.28 million, a P/E ratio of -3.29, a price-to-earnings-growth ratio of 1.50 and a beta of -0.25.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.91. The firm had revenue of $51.08 million for the quarter, compared to analyst estimates of $0.81 million. Prothena had a negative return on equity of 43.44% and a negative net margin of 260.92%. As a group, research analysts expect that Prothena Corporation plc will post 0.18 EPS for the current fiscal year.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.